[go: up one dir, main page]

CU20180025A7 - Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue - Google Patents

Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue

Info

Publication number
CU20180025A7
CU20180025A7 CU2018000025A CU20180025A CU20180025A7 CU 20180025 A7 CU20180025 A7 CU 20180025A7 CU 2018000025 A CU2018000025 A CU 2018000025A CU 20180025 A CU20180025 A CU 20180025A CU 20180025 A7 CU20180025 A7 CU 20180025A7
Authority
CU
Cuba
Prior art keywords
dengue virus
preparation
against dengue
tetravalent vaccine
tetravalent
Prior art date
Application number
CU2018000025A
Other languages
English (en)
Other versions
CU24579B1 (es
Inventor
Neuza Maria Frazatti Gallina
Original Assignee
Fund Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fund Butantan filed Critical Fund Butantan
Publication of CU20180025A7 publication Critical patent/CU20180025A7/es
Publication of CU24579B1 publication Critical patent/CU24579B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Proceso para preparar una vacuna tetravalente atenuada contra el virus del dengue y producto del mismo. La presente invención también se refiere a un proceso de preparación de una vacuna tetravalente contra el dengue para su administración a un sujeto, a un método para inducir una respuesta inmune contra los serotipos 1, 2, 3 y 4 del virus del dengue en un paciente y a un kit para una vacuna tetravalente contra el dengue.</p>
CU2018000025A 2015-09-08 2016-09-06 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue CU24579B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/847,422 US10004795B2 (en) 2015-09-08 2015-09-08 Process for preparing an attenuated tetravalent dengue vaccine
PCT/BR2016/050224 WO2017041156A1 (en) 2015-09-08 2016-09-06 Process for preparing an attenuated tetravalent dengue vaccine

Publications (2)

Publication Number Publication Date
CU20180025A7 true CU20180025A7 (es) 2018-11-06
CU24579B1 CU24579B1 (es) 2022-02-04

Family

ID=56268413

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000025A CU24579B1 (es) 2015-09-08 2016-09-06 Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue

Country Status (17)

Country Link
US (2) US10004795B2 (es)
EP (1) EP3347043A1 (es)
JP (1) JP6968070B2 (es)
CN (1) CN108289945B (es)
AR (1) AR105966A1 (es)
AU (1) AU2016318349B2 (es)
BR (1) BR102015030332B1 (es)
CL (1) CL2018000609A1 (es)
CO (1) CO2018003451A2 (es)
CR (1) CR20180202A (es)
CU (1) CU24579B1 (es)
EC (1) ECSP18026090A (es)
HK (1) HK1258584A1 (es)
MX (2) MX2018002901A (es)
PE (1) PE20181135A1 (es)
TW (1) TWI733694B (es)
WO (1) WO2017041156A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211814A1 (es) 2013-03-15 2021-09-14 Takeda Vaccines Inc Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EP3697897A4 (en) 2017-10-16 2022-02-23 Serum Institute Of India Private Limited STABLE VACCINE COMPOSITIONS WHICH INCLUDE i.a. LIVE ATTACHED RECOMBINANT FLAVIVIRS CONTAIN, AND PROCESS FOR THEIR PRODUCTION
GEP20237539B (en) 2017-12-07 2023-09-11 Merck Sharp & Dohme Llc Formulations of dengue virus vaccine compositions
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2677348T3 (es) * 2002-05-03 2018-08-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Un virus del dengue quimérico recombinante rDEN3/4delta 30(ME), rDEN2/4delta30(ME) o rDEN1/4delta30(ME) que contiene una deleción de 30 nucleótidos (delta30) en una sección de la región no traducida en 3' del genoma del dengue de tipo 4, en donde dicha deleción de 30 nucleótidos se corresponde con la estructura tallo-bucle de TL2
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
AU2004312352B2 (en) * 2003-12-19 2010-08-19 Wyeth Serum-free vero cell banking process
WO2006066332A1 (en) * 2004-12-23 2006-06-29 Murray Goulburn Co-Operative Co Limited Method of manufacture of a modified milk powder suitable as a rennet casein extender or replacer
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
AU2014240246B2 (en) * 2008-12-05 2017-08-10 Takeda Vaccines, Inc. Compositions, methods and uses for inducing viral growth
PE20211814A1 (es) * 2013-03-15 2021-09-14 Takeda Vaccines Inc Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
EP3052106A4 (en) * 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine

Also Published As

Publication number Publication date
JP6968070B2 (ja) 2021-11-17
EP3347043A1 (en) 2018-07-18
BR102015030332A2 (pt) 2016-07-05
TWI733694B (zh) 2021-07-21
CL2018000609A1 (es) 2018-08-17
US20180256702A1 (en) 2018-09-13
CO2018003451A2 (es) 2018-11-30
BR102015030332B1 (pt) 2019-11-05
US10004795B2 (en) 2018-06-26
US20170065701A1 (en) 2017-03-09
HK1258584A1 (zh) 2019-11-15
AU2016318349A1 (en) 2018-04-19
MX2021013109A (es) 2021-11-17
CN108289945B (zh) 2022-05-31
JP2018527408A (ja) 2018-09-20
CN108289945A (zh) 2018-07-17
PE20181135A1 (es) 2018-07-17
WO2017041156A1 (en) 2017-03-16
AR105966A1 (es) 2017-11-29
MX2018002901A (es) 2018-09-18
TW201718008A (zh) 2017-06-01
US10201600B2 (en) 2019-02-12
AU2016318349B2 (en) 2019-10-17
ECSP18026090A (es) 2018-10-31
CU24579B1 (es) 2022-02-04
CR20180202A (es) 2018-08-10

Similar Documents

Publication Publication Date Title
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
EP4218807A3 (en) Zika virus vaccine
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
PH12018500127A1 (en) Vaccine compositions
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MY192739A (en) Vaccine compositions against dengue virus diseases
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX2024003337A (es) Composiciones inmunogenicas contra la influenza.
IL259451A (en) Live virus with accumulation of dengue fever of a weakened nature and vaccination of dengue fever containing identical antigens
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
MX2024007379A (es) Vacunas para el virus del papiloma humano y metodos para su uso.